Literature DB >> 24781891

Reliability of maximal cardiopulmonary exercise testing in men with prostate cancer.

Jessica M Scott1, Whitney E Hornsby, Amy Lane, Aarti A Kenjale, Neil D Eves, Lee W Jones.   

Abstract

PURPOSE: To accurately assess exercise interventions and to evaluate acute and chronic cardiovascular effects in patients with early-stage cancer, consistently reliable functional outcome measures must be obtained. An incremental cardiopulmonary exercise test (CPET) with gas exchange measurement to assess peak oxygen consumption (V˙O2peak) provides the gold standard outcome of cardiorespiratory fitness.
METHODS: In the context of a randomized controlled trial, 40 patients with prostate cancer (mean age, 59 ± 7 yr) after radical prostatectomy performed two maximal CPET within 5.6 ± 5.5 d of each other. Incremental treadmill tests were performed in the morning under identical laboratory conditions. Reliability and within-subject variability from test 1 to test 2 for peak and submaximal variables were assessed by correlation coefficients, intraclass correlations (ICC), Bland-Altman plots, coefficient of variation, and paired t-tests.
RESULTS: There was high reliability between CPET for V˙O2peak (r = 0.92; P < 0.001; ICC, 0.900), ventilatory threshold (r = 0.88; P < 0.001; ICC, 0.927), minute ventilation-carbon dioxide production relation (V˙E/V˙CO2) (r = 0.86; P < 0.001; ICC, 0.850), and peak heart rate (r = 0.95; P < 0.001; ICC, 0.944). However, high within-subject variability was observed for all CPET parameters (mean coefficient of variation, 4.7%). Compared with those for test 1, significantly higher mean values were observed for V˙O2peak (27.0 ± 5.6 vs 28.1 ± 5.3 mL·kg·min, P < 0.05), ventilatory threshold (1.91 ± 0.5 vs 1.97 ± 0.4 L·min, P < 0.05), and V˙E/V˙CO2 (31.3 ± 5.8 vs 32.8 ± 3.4, P < 0.05) in test 2.
CONCLUSIONS: These findings indicate the presence of significant, and potentially clinically important, variability in CPET procedures in men with clinically localized prostate cancer and have important implications for the application and use of CPET to evaluate the efficacy of interventions to improve aerobic capacity in the oncology setting.

Entities:  

Mesh:

Year:  2015        PMID: 24781891      PMCID: PMC4376254          DOI: 10.1249/MSS.0000000000000370

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  26 in total

1.  Technical considerations related to the minute ventilation/carbon dioxide output slope in patients with heart failure.

Authors:  Ross Arena; Jonathan Myers; Syed Salman Aslam; Elsa B Varughese; Mary Ann Peberdy
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

2.  Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer.

Authors:  Lee W Jones; Neil D Eves; John R Mackey; Carolyn J Peddle; Mark Haykowsky; Anil A Joy; Kerry S Courneya; Keith Tankel; Jennifer Spratlin; Tony Reiman
Journal:  Lung Cancer       Date:  2006-11-17       Impact factor: 5.705

3.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

Review 4.  Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations.

Authors:  Lee W Jones; Neil D Eves; Mark Haykowsky; Anil A Joy; Pamela S Douglas
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

5.  Reproducibility of cardiopulmonary parameters during exercise in patients with chronic cardiac failure. The need for a preliminary test.

Authors:  J S Elborn; C F Stanford; D P Nicholls
Journal:  Eur Heart J       Date:  1990-01       Impact factor: 29.983

6.  Repeatability of aerobic capacity measurements in Parkinson disease.

Authors:  Leslie I Katzel; John D Sorkin; Richard F Macko; Barbara Smith; Frederick M Ivey; Lisa M Shulman
Journal:  Med Sci Sports Exerc       Date:  2011-12       Impact factor: 5.411

7.  Maximal oxygen uptake as a parametric measure of cardiorespiratory capacity.

Authors:  Megan N Hawkins; Peter B Raven; Peter G Snell; James Stray-Gundersen; Benjamin D Levine
Journal:  Med Sci Sports Exerc       Date:  2007-01       Impact factor: 5.411

8.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

9.  Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.

Authors:  Lee W Jones; Whitney E Hornsby; Stephen J Freedland; Amy Lane; Miranda J West; Judd W Moul; Michael N Ferrandino; Jason D Allen; Aarti A Kenjale; Samantha M Thomas; James E Herndon; Bridget F Koontz; June M Chan; Michel G Khouri; Pamela S Douglas; Neil D Eves
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096

10.  Long-term reproducibility of respiratory gas exchange measurements during exercise in patients with stable cardiac failure.

Authors:  J S Janicki; S Gupta; S T Ferris; P A McElroy
Journal:  Chest       Date:  1990-01       Impact factor: 9.410

View more
  6 in total

1.  Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jessica M Scott; Emily C Zabor; Emily Schwitzer; Graeme J Koelwyn; Scott C Adams; Tormod S Nilsen; Chaya S Moskowitz; Konstantina Matsoukas; Neil M Iyengar; Chau T Dang; Lee W Jones
Journal:  J Clin Oncol       Date:  2018-06-12       Impact factor: 44.544

2.  The Siconolfi step test: a valid and reliable assessment of cardiopulmonary fitness in older men with prostate cancer.

Authors:  Agnieszka Lemanska; Karen Poole; Jonathan J Aning; Bruce A Griffin; Ralph Manders; John M Saxton; Joe Wainwright; Sara Faithfull
Journal:  Eur Rev Aging Phys Act       Date:  2019-01-10       Impact factor: 3.878

3.  Effects of supervised aerobic exercise on cardiorespiratory fitness and patient-reported health outcomes in colorectal cancer patients undergoing adjuvant chemotherapy-a pilot study.

Authors:  Eva M Zopf; Holger Schulz; Jonas Poeschko; Kerstin Aschenbroich; Thomas Wilhelm; Ernst Eypasch; Elmar Kleimann; Kai Severin; Jutta Benz; Enwu Liu; Wilhelm Bloch; Freerk T Baumann
Journal:  Support Care Cancer       Date:  2021-10-08       Impact factor: 3.603

4.  Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial.

Authors:  Jessica M Scott; Samantha M Thomas; James E Herndon; Pamela S Douglas; Anthony F Yu; Valerie Rusch; James Huang; Catherine Capaci; Jenna N Harrison; Kurtis J Stoeckel; Tormod Nilsen; Elisabeth Edvardsen; Meghan G Michalski; Neil D Eves; Lee W Jones
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-10-17       Impact factor: 12.910

5.  Physiological Effort in Submaximal Fitness Tests Predicts Weight Loss in Overweight and Obese Men with Prostate Cancer in a Weight Loss Trial.

Authors:  Andrew D Frugé; John A Dasher; David Bryan; Soroush Rais-Bahrami; Wendy Demark-Wahnefried; Gary R Hunter
Journal:  Int J Cancer Clin Res       Date:  2017-10-16

6.  High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial.

Authors:  J E M Blackwell; B Doleman; C L Boereboom; A Morton; S Williams; P Atherton; K Smith; J P Williams; B E Phillips; J N Lund
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-03-10       Impact factor: 5.554

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.